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Abstract: Neuropathic pain is a kind of pain related with functional abnormality of neurons. Despite large progress in pharmacotherapy, 
neuropathic pain is still considered an unmet need. Nowadays, there are few drugs registered for this condition, such as pregabalin, 
gabapentin, duloxetine, carbamazepine, and lidocaine. Among them, pregabalin, gabapentin and carbamazepine are well known antiepi-
leptic drugs.  
Among the group of new antiepileptic drugs, which are addressed to 1% of human world population suffering from seizures, it turned out 
that 30% of the seizures resistant to pharmacotherapy has not enough market to justify the costs of drug development. Therefore, it is al-
ready a phenomenon that researchers turn their projects toward a larger market, related with possible similar mechanism. 
Anticonvulsant mechanism of action is in the first place among primary indications for drugs revealing potential analgesic activity. 
Therefore, many drug candidates for epilepsy, still in preclinical stage, are being evaluated for activity in neuropathic pain.  
This review is focusing on antiepileptic drugs, which are evaluated for their analgesic activity in major tests related with neuropathic 
pain. Relation between structure, mechanism of action and result in tests such as the Chung model (spinal nerve ligation SNL), the 
Bennett model (chronic constriction injury of sciatic nerve CCI) and other tests are considered. The first examples are carbamazepine, 
gabapentin, and lacosamide as drugs well established in epilepsy market as well as drug candidates such as valnoctamide, and other val-
proic acid derivatives, novel biphenyl pyrazole derivatives, etc. Moreover, clinical efficacy related with listed animal models has been 
discussed. 
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I. INTRODUCTION 
Neuropathic pain is a kind of pain caused by functional abnor-
mality of neurons, related with their damage. Despite large progress 
in pharmacotherapy, neuropathic pain as an indication is still con-
sidered an unmet need, since 50% of patients suffer from the pain 
despite treatment [1]. Nowadays, there are few drugs registered for 
this condition, such as amitriptyline [2], pregabalin [3], gabapentin 
[4], duloxetine [5], carbamazepine [6], lidocaine [7], lamotrigine 
[8], and opioids [9]. Among them, pregabalin, gabapentin, carba-
mazepine, and lamotrigine are well known and well established 
antiepileptic drugs (AEDs). Furthermore, gabapentin is considered 
the leading drug in neuropathic pain treatment.  
Among the group of new AEDs, which are addressed to 1% of 
human world population suffering from seizures, it turned out that 
30% of the seizures resistant to pharmacotherapy has not enough 
market to justify the costs of drug development. Even though the 
number of epileptic conditions is still rising, as epileptogenesis 
becomes better understood, the new conditions such as myoclonic 
astatic seizures, Lennox-Gastaut syndrome, or severe myoclonic 
epilepsy in infancy, or even epilepsy in pregnancy or childhood are 
a difficult market to develop new drugs. Most recent AEDs have 
been developed through the Antiepileptic Drug Development Pro-
gram (ADD) at National Institutes of Neurological Disorders and 
Stroke, (NINDS), National Institutes of Health (NIH), Rockville, 
MD, USA under supervision of prof. James P. Stables or with some 
support from the Institute [10].  
Well known AEDs revealing certain mechanisms involved in 
the genesis and maintenance of hyperexcitability, are an important 
area of progress in the research and therapy of neuropathic pain. 
Currently, among primary indications for drugs revealing potential 
analgesic activity in neuropathic pain in the first place most often 
there is anticonvulsant mechanism of action. Therefore, many drug 
candidates for epilepsy, still in preclinical stage, are being evaluated 
for activity in neuropathic pain. Mechanisms of action represented  
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by analgesic drugs effective in neuropathic pain are also typical in 
most cases of antiepileptic drugs:  
• ion channel modulators (sodium, potassium, and calcium),  
• GABA (-aminobutyric acid) modulators,  
• glutamate receptor modulators,  
• monoamine modulators,  
• cannabinoid receptor modulators,  
• opioids, and 
• topical capsaicin treatments. 
Among the above mechanisms, the major ion channel modula-
tors and GABA modulators are typical mechanisms of action of 
AEDs. 
Neuropathic pain has been considered as a progressive nervous 
system disease in which spread of pain generating mechanisms is 
due to the biochemical reactions in the nervous system [11]. Some 
systemic reviews have drawn attention to new information of mo-
lecular, biochemical and neuroanatomical mechanisms of neuro-
pathic pain which have identified a potential therapeutic target for 
the treatment of persistent pain.  
Peripheral neuropathic pain may be caused by mechanical nerve 
injury, metabolic disease, neurotropic viral disease, neurotoxicity or 
tumor. Those factors may result in pathophysiological changes in 
peripheral as well as in central nervous system. Spinal cord injury, 
stroke or multiple sclerosis remain most common reasons of central 
neuropathic pain. Differentiation of the peripheral and central sites 
of the pain is possible considering only the etiology because those 
mechanisms are initiators of the cascade of changes in all parts of 
nervous system. Another possible etiology of persistent pain is 
related with inflammatory mechanisms but undoubtedly there is a 
fundamental difference in the neuronal pathways responsible for 
neuropathic and inflammatory pain so they remain distinct in terms 
of their eiology and clinical features [12]. Inflammation involves 
accumulation of endogenous factors (such as mast cells, basophils, 
platelets, macrophages, neutrophils, endothelial cells, keratinocytes, 
and fibroblasts) which can infiltrate the changed nerves. Addition-
ally, nociceptors express one or more cell-surface receptors capable 
of responding to these agents, which together lead to enhancing 
excitability of the nerve fiber. Reducing inflammatory pain is 
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commonly reached by inhibition of synthesis or accumulation of 
those pro-inflammatory factors. Another approach is to block the 
action at the nociceptor. The progress has been made in identifying 
new target molecules in possible therapeutic strategies of treating 
inflammatory pain. There are nerve growth factor (NGF), interleu-
kin-1 (IL-1), IL-6, tumor necrosis factor  (TNF-) and transient 
receptor potential (TRP) cation channels among them are nocicep-
tor channels responsible for sensitivity to heat – TRPV1 (also 
known as vanilloid receptor or capsaicin receptor) or chemical 
stimuli – TRPA1 [13].  
Great progress has been also made in understanding mecha-
nisms implicated in central site of neuropathic pain. Among others, 
alteration in glutamatergic neurotransmission/NMDA receptor-
mediated sensitization, loss of GABAergic and glycinergic controls 
(disinhibition) and glial-neuronal interactions have been described 
[13]. Undoubtedly voltage-gated sodium channels (NaV), especially 
their specific isoforms (NaV1.1-NaV1.9), constitute an attractive 
target in pharmacotherapy of neuropathic pain. It has been shown in 
both animal studies and human tissues that nerve injury induces 
dynamic regulation of sodium channel expression in dorsal root 
ganglion [14]. But still it is not clearly stated which sodium channel 
isoforms are responsible for human neuropathic pain syndromes. 
However, NaV1.8 and NaV1.3 are promising molecules [15]. Recent 
studies showed that T-type (CaV3) channels are also in interest as 
target molecules in neuropathic pain [16]. 
Neuropathic pain can be divided into three major disorders: dia-
betic neuropathic pain (DNP), post-herpetic neuralgia (PHN), and 
Human Immunodeficiency Virus-associated neuropathic pain 
(HIVNP). Approximately 20-24% of diabetes patients suffer from 
DNP [17]. Other neuropathies to be mentioned are trigeminal neu-
ralgia, thalamic syndrome, phantom limb pain, tabetic pain, etc. 
The prevalence in the USA is 0.054% for DNP, and 0.185% for 
PHN [18].  
Preclinical evaluating tests for neuropathic pain are based on 
mice or rats and involve surgery or chemical stimuli. Animal mod-
els of pain have been designed for proper evaluation of drug candi-
dates for potential use in various pain types.The following list is 
limited to the kinds of assays which have been used for evaluation 
of antiepileptic drugs. 
• Tight Ligation of Spinal Nerves (SNL-Spinal Nerve Liga-
tion), i.e. the Kim and Chung model, Chung model – the 
procedure involves spinal L5 or L5-L6 nerves ligation in 
rats; the test allows assessment of activity in alleviating me-
chanic allodynia and mechanic hyperalgesia, as well as 
thermal hyperalgesia. The pain is developed in the hind 
limb at the side of the ligation. The symptoms remain for 49 
days and the test is concerned as a model for acute pain 
[19].  
• Loose Ligation of the Sciatic Nerve (CCI-chronic constric-
tion injury), i.e. the Bennett and Xie model, Bennett model 
– the procedure is performed in rats and causes develop-
ment of inflammation as a response to presence of the 
thread, which in turn leads to damage of the neuron and de-
velopment of neuropathic pain. The phenomena related 
with the model are mechanic allodynia, mechanic hyperal-
gesia, and thermal hyperalgesia. The neuropathic pain is 
developed up till 2 weeks after the procedure. The CCI 
model is concerned as a test for chronic pain [19]. 
• Streptozocin test – the test for diabetic neuropathy in mice 
or rats; the animals that have developed diabetes post 
streptozocin i.p.(intraperitoneal) administration, are 
administered a tested substance and response to nociceptive 
stimuli is observed [20]. 
Additionally, the formalin test is usually performed to study 
whether the compound possesses any analgesic activity. The test 
involves injection of formalin to a mouse or a rat paw which results 
in neuronal damage, exhibited by two phases of pain response: 
acute phase and inflammatory phase [21, 22]. 
As the tests used for verification of analgesic activity must in-
duce pain in animals, in order to spare the animals, the negative 
controls are often represented by: 
• a group of animals which have received injection with placebo, 
• sham-operated rats (in the CCI and SNL models) – the animals 
have the nerve isolated but not ligated, or 
• the sensitivity is tested at the opposite side of the ligation. 
Nociception is related with the following phenomena: 
• allodynia – pain caused by non-nociceptive stimulus, e.g. 
due to lowering sensitivity threshold of a receptor. Tactile 
allodynia occurs probably due to central changes triggered 
by increased activity of nociceptors but in contrast, more 
recent findings suggest that nociceptors are not required for 
the induction of mechanical hypersensitivity[23]. 
• analgesia – lack of feeling pain in place of nociceptive 
stimulus; 
• anesthesia – lack of all perception types; 
• hyperalgesia – increased sensitivity to pain; the mechanism 
of hyperalgesia is probably connected with functions of 
thalamus, anterior cingulate cortex and central nucleus of 
the amygdala [23]. 
• neuralgia – attacks of short time pain not related with any 
cause, without damage of the nervous system; 
• paresthesia – wrong perception of a pain stimulus. 
The observed allodynia types in the models involve: 
• cold allodynia – response to ethyl chloride spray stimula-
tion – the total time of licking the limb is added; or placing 
a drop of acetone on the foot and observing its withdrawal; 
acetone is placed 5 times, each time after a 5 min. break; 
the endpoint is the amount of acetone followed by with-
drawal of the limb * 100, 
• tactile allodynia – response to touch by von Frey filaments 
respective to various strengths and masses; the endpoint is 
number of touches followed by withdrawal of the limb * 
100.  
The aim of this review is to show antiepileptic drugs which are 
evaluated for their analgesic activity in major tests related with 
neuropathic pain. Relation between structure, mechanism of action 
and result in tests such as the Chung model – the most popular test, 
the Bennett model and other tests are considered.  
Moreover, some authors have approached similar reviews in the 
past [12, 13, 23, 24], however, large progress has been made in 
terms of knowledge underlying molecular and cellular mechanisms 
of disease development as well as possible mechanisms of action of 
potential drugs, and clinical efficacy of drugs. 
II. ANTIEPILEPTIC DRUGS AND THEIR EVALUATION 
FOR PAIN TREATMENT 
The currently used antiepileptic drugs have been secondarily 
evaluated in neuropathic pain models, which means that neuro-
pathic pain is their second indication. This could be the reason why 
such compounds show modest efficacy in neuropathic pain. How-
ever, new drugs have some advantages, such as improved profile 
and pharmacokinetics and more favorable tolerability [25]. This is 
why this review is focused on comparison of the activity in epilepsy 
with activity in neuropathic pain in the same species and routes of 
administration. The drugs have been grouped with mechanisms of 
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action and secondarily by structure similarities. The results pre-
sented in the text are summarized in Table 1. 
1. Ion Channel Modulators 
Ion channel modulators exhibit great potential in neuropathic 
pain. Lacosamide, which represents sodium channel blockers, has 
become very popular AED in the pain treatment [15]. However, 
retigabine – a potassium channel opener, also turned out to be ac-
tive in pain models, as shown below. Other channels related with 
analgesic and anticonvulsant activity are calcium channels. 
Voltage-gated sodium channels have been shown to play a 
critical role in neuropathic pain. Still, their non-specific inhibition is 
also a mechanism of action for the oldest antiepileptic drugs. 
Within the process of neuropathic pain formation, due to GDNF 
(glial cell derived neurotrophic factor) enhanced activity, voltage-
gated sodium channel (NaV) subtype 1.3 is induced, causing suscep-
tibility to stimuli. Moreover, in the non-destructed part of the neu-
ron – NaV1.7 and 1.8 channels are overexpressed [18]. This is why 
sodium channels are a promising target for drug candidates, how-
ever, for the ones that are selective enough. Recent studies have 
shown that by targeting specifically subtypes NaV1.1 and 1.2 a 
molecule can reduce seizures [26] and not neuropathic pain. There-
fore, specificity towards NaV1.3, 1.7, and 1.8 versus NaV1.1 and 1.2 
could differentiate between analgesics and antiepileptic drugs, re-
spectively. 
Inhibition of sodium channels is the mechanism seen for the 
very first antiepileptic drugs and for some novel drug candidates: 
carbamazepine, oxcarbazepine, lamotrigine, lacosamide, zoni-
samide, topiramate, and biaryl pyrazoles. Opening potassium chan-
nels is a main mechanism for retigabine, but the biaryl pyrazole 
derivative by Merck also exhibits some affinity. Calcium channels 
are influenced by zonisamide, topiramate, and the mentioned biaryl 
pyrazole derivative, and the 2 subunits of channels are inhibited 
by pregabalin and gabapentin. 
Carbamazepine and Oxcarbazepine  
Carbamazepine (5H-dibenzo[b,f]azepine)-5-carboxamide) (Fig. 
1) exhibits ED50s (effective dose in 50% animals) in MES (maxi-
mum electroshock seizures) 7.81 mg/kg b.w. (body weight) mice, 
i.p. and 17 mg/kg b.w. mice, p.o.(per os) [10, 27] (Table 1). In hu-
mans, this iminostilbene derivative is active in simple partial, com-
plex partial, and generalized tonic-clonic seizures, while inactive or 
deleterious in absence or myoclonic seizures [28]. It is a drug of 
first choice in the treatment of epilepsy, also during pregnancy. Its 
monotherapy in mothers during conception causes malformations 
only in 1.3%-8.7% newborn children up to 1 year of age, if mothers 
had been taking doses ranging from <400 mg/day-1000 mg/day 
[29]. 
This AED administered s.c. (subcutaneously) to rats, signifi-
cantly reduces spontaneous neuronal activity in the Chung model 
(SNL) at doses 0.5-22.5 mg/kg b.w. [30]. It is also active in reduc-
tion of inflammatory exudate caused by implantation of car-
rageenan soaked sponges in rats with ED50 of 27.5 mg/kg b.w. (rats, 
p.o.) [31], while the anti-inflammatory activity is not necessarily 
related with the anticonvulsant mechanism of action. The analgesic 
activity in humans has been widely discussed, since the first report 
on activity of carbamazepine in trigeminal neuralgia was reported 
in 1962 by Blom and carbamazepine is now considered a drug of 
choice for this condition [32, 33]. 
Oxcarbazepine (10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-
5-carboxamide) (Fig. 1), a well known 10-oxoderivative of carba-
mazepine, inhibits voltage-gated sodium channels, which is the 
main mechanism of action in seizures management. Its additional 
mechanisms of action, apart from blocking voltage-gated sodium 
channels, are increase of potassium conductance and modulation of 
calcium channels. Preclinical evaluation in epilepsy reveals ED50 
6.1 mg/kg b.w. in rats, i.p. with TD50 (toxic dose in 50% animals, 
measured by rotarod) 40.1mg/kg b.w. (rats, i.p.) [34]. More data are 
presented in Table 1. Oxcarbazepine is a second generation antiepi-
leptic drug with proved efficacy in monotherapy and combination 
therapy in managing partial epileptic seizures. It is relatively better 
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Fig. (1). Chemical structures of carbamazepine and oxcarbazepine. 
Oxcarbazepine was proved to be active in the Chung model in a 
dose-dependent manner, 15 min. after i.p. administration of 10-50 
mg/kg b.w. (Table 1) [35]. Therefore, it can be effective in various 
neuropathic pain conditions that are accompanied by allodynia or 
hyperalgesia. However, it was not proved whether the analgesic 
activity mechanism depends on NaV channels. Other mechanisms 
related with pain models for carbamazepine and oxcarbazepine are 
associated with NMDA (N-methyl-D-aspartic acid) receptor [31], 
as well as A1 (adenine) receptor [36] which possibly revitalizes the 
opioid system [37]. The rationale for use of oxcarbazepine was also 
discussed in humans and its activity in alleviating pain related with 
trigeminal neuralgia has been proved, as well as in diabetic neu-
ropathy [33, 38, 39]. However, this drug failed in another study for 
DNP [40]. 
Its efficacy at doses 900-2100 mg/day is comparable to carba-
mazepine taken 400-1200 mg/day in trigeminal neuralgia. Also in 
clinical trials – oxcarbazepine proved to be better tolerated than 
carbamazepine as fewer incidents of vertigo, ataxia, dizziness, and 
fatigue were reported [33]. 
Lamotrigine 
Lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, 
LTG) (Fig. 2) is a well known anticonvulsant, whose mechanism of 
action is basically inhibition of voltage- and use-dependent sodium 
channels and calcium channels, supported by inhibition of release 
of excitatory aminoacids. In preclinical tests it proved efficacy in 
MES at ED50=33.2 M/kg b.w. (mice, i.p.), in 6Hz test ED50=100.4 
M/kg b.w. (mice, i.p., 32 mA), in corneal kindling ED50=37.1 
M/kg b.w. (mice, i.p.) and in hippocampal kindling ED50= 61.3 
M/kg b.w. (rats, i.p.). As hippocampal kindling is a model for 
epileptogenesis, the AED should slow down development of the 
disease in patients [41]. Lamotrigine is also active in sound induced 
seizures (AGS, audiogenic seizures) in Frings mice i.p. with ED50 
of 2.39 mg/kg b.w. TD50 in rotarod test is 30 mg/kg b.w. (mice, i.p.) 
and 411 mg/kg b.w. (rats, p.o.) [42, 43]. Clinical trials in epilepsy 
show that lamotrigine is similarly effective to carbamazepine. 
However, it may have a more favorable long-term effect on cogni-
tive function when compared to carbamazepine (in terms of pho-
nemic verbal fluency and stroop color-word interference) [44]. 
Clinical safety of this AED when used in pregnancy is also compa-
rable to carbamazepine – it causes malformations only in 1.7%-
4.5% newborn children up to 1 year of age, if mothers had been 
taking doses ranging from <300 mg/day-300 mg/day [29]. Lamo-






Fig. (2). Chemical structure of lamotrigine. 
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Lamotrigine was active in the Chung model with ED50 of 12 
mg/kg b.w. (originally 47 M/kg) rats, p.o. [46], compared to MES 
ED50 1.26 mg/kg b.w. rats, p.o. and 7.47 mg/kg mice, i.p. (Table 1).  
It is more effective than carbamazepine in clinical trials for use 
in trigeminal neuralgia. The recommended doses are 25 mg/day, 
increased by 25 mg every seventh day until the effect or until 
maximum dose 400 mg/day is achieved [47]. Lamotrigine has been 
shown to relieve pain associated with DNP, central post-stroke pain 
and chemotherapy-induced neuropathic pain [48-50]. Additionally, 
the analgesic efficacy of lamotrigine in the treatment of painful 
HIV-associated distal sensory polyneuropathy (DSP) was stated 
[51]. The typical adverse event for this drug is skin rash, and the 
chance for it increases with the dose. Other side effects are head-
ache and cough [45]. 
Lacosamide 
Lacosamide (harkoseride, SPM927, ADD 234037, 2(R)-
acetamido-N-benzyl-3-methoxypropionamide) (Fig. 3) exerts activ-
ity by means of selective enhancement of slow inactivation of volt-
age-gated sodium channels [52]. The enantiomer R is active in MES 
at dose 4.5 mg/kg b.w. (mice, i.p.) and 3.9 mg/kg b.w. (rats, i.p.). 
Lacosamide is also active in audiogenic seizures (Frings mice) and 
kindling models as well (Table 1) [53]. This AED was found active 
in cases of partial seizures and in simple motor status epilepticus 
(with levetiracetam) [54] as well as in refractory nonconvulsive 










Fig. (3). Chemical structure of lacosamide.  
The analgesic activity of lacosamide has been widely examined. 
Its only mechanism of action is block of sensory neuronal NaV 
channels, since it does not bind significantly to any of over 50 other 
targets at 10 M concentration [15, 56]. Lacosamide proved to be 
active in models for cancer-related pain [57], in the Chung model 
[58, 59] and the streptozocin model for diabetic neuropathy in the 
following tests: cold bath test (thermal allodynia), hot plate test 
(thermal allodynia and hyperalgesia), paw pressure withdrawal test 
(mechanical hyperalgesia), and brushing test (dynamic allodynia) 
[60]. The preclinical properties have been subject to other reviews 
as well [53]. Its activity in inflammatory pain also has been proved 
in the formalin test, at dose 32 mg/kg b.w. (mice, i.p.), in the car-
rageenan-induced thermal and mechanical hyperalgesia in rats (at 
32 mg/kg b.w. and 8 mg/kg b.w., respectively, i.p.) and adjuvant-
induced arthritis in rats (at 40 mg/kg b.w.) [61]. 
Consistently with activity in the streptozocin model, lacosamide 
is also active in DNP in humans with proved efficacy at doses 200-
600 mg/day, while its most common adverse events are dizziness, 
headache, nausea, and – at 600 mg/day – tremor [62, 63]. Surpris-
ingly, subsequent trials have failed to find an effect [64]. 
Zonisamide 
Zonisamide (1,2-benzisoxazole-3-methanesulfonamide, ZSM) 
(Fig. 4) protects against seizures via inhibition of NaV channels 
(produces use- and voltage dependent blockade and slows the rate 
of recovery) as well as T-type calcium channels. Other additional 
mechanisms have an influence on neurotransmitter systems, i.e. 
GABAergic (through binding to GABA receptors and influencing 
GABA transport), dopaminergic and serotoninergic (increasing 
extracellular levels of dopamine or serotonin), glutaminergic, and 
cholinergic. It also inhibits carbonic anhydrase,which is too weak to 
influence its anticonvulsant activity, but affects its pharmacokinet-
ics [65-67]. 
Consistently with multiplicity of mechanisms of action, ZSM is 
also active in many animal models, exhibiting ED50=19.6 mg/kg 
b.w. (mice, p.o.) and ED50=7.9 mg/kg b.w. (rats, p.o.) in MES, ac-
tivity in hippocampal seizures (rats) and amygdala kindled seizures 
in rats and in cats [68]. The molecule was developed primarily by 
Dainippon, recently by Elan and Eisai, and presents broad spectrum 
activity in clinical trials: adjunct therapy in partial and generalized 
(tonic-clonic) seizures in adults as well as in monotherapy in chil-








Fig. (4). Chemical structure of zonisamide. 
Consistently with multiplicity of mechanisms of action, analge-
sic activity of ZSM is also diverse. It has been tested in thermal 
hyperalgesia and mechanical allodynia [70]. Zonisamide is also 
active in inflammatory and diabetic neuropathic pain. The former 
was shownwith use of the formalin test, where zonisamide at doses 
3 and 10 mg/kg b.w. (mice) reduced licking behavior in both acute 
and inflammatory phases of the test. The effect was observed after 
intrathecal administration as well, and the concluded mechanism of 
analgesia is probably partially peripheral [20]. Analgesic use in 
various (not specified) neuropathic pain syndromes in clinics has 
been reviewed, confirming its activity at doses 100 mg/day [67]. As 
a consequence of its sulfonamide moiety, the drug is contraindi-
cated in patients with allergies to sulfonamides, and may cause 
serious side effects such as epidermal necrolysis, Stevens-Johnson 
syndrome, leucopenia, and aplastic anemia, as well as abnormal 
thinking, dizziness, nausea, headache, etc. [67]. 
Topiramate 
Topiramate (2,3:4,5-bis-O-(1-methylethylidene)--D-fructo-
pyranose sulfamate, TPM) (Fig. 5) exerts activity via multiple 
mechanisms. They are inhibition of sodium channels [71] and 
antagonism of AMPA/kainite (-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) receptor [72] as well as enhancement of 
GABAA receptor action, inhibition of L-type calcium channels, and 
inhibition of carbonic anhydrase (similar to zonisamide, this activ-
ity does not contribute to anticonvulsant properties). The activity in 
MES is supported by ED50 15.8 mg/kg b.w. (rats, p.o.) and 47.6 
mg/kg b.w. (mice, p.o.) [71]. Moreover, in experimental epilepsy 
models the ED50 for MES in mice, p.o. is 47.6 mg/kg b.w. and in 
rats, p.o. it is 15.8 mg/kg b.w. The dose 20 mg/kg has proved effec-
tiveness in neuroprotective studies in the stroke model [73]. It is 
indicated in partial and generalized seizures, as well as in intracta-
ble childhood epilepsies, at doses 125-400 mg/day for children age 
2-16 years (not to exceed 800 mg/day)  – Lennox-Gastaut Syn-
drome (ED50=5.1-5.8/mg/kg/day), West syndrome at 15-29 
mg/kg/day, and in monotherapy. Adverse events are somnolence, 
anorexia, fatigue, attention difficulties, aggression and weight loss. 
Neuropsychiatric events are less frequent in children than in adults, 











Fig. (5). Chemical structure of topiramate.  
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The estimated ED50 for topiramate’s anti-allodynic effect is 
30/mg/kg b.w., rats, i.p. Chronic constriction injury was also per-
formed in rats at 20 mg/kg b.w., i.p.(Table 1) [73, 75]. Clinical 
proof of effectiveness in pain indication has been reviewed, de-
scribing positive results in clinical trials regarding trigeminal neu-
ralgia (also in multiple sclerosis patients), intercostal neuralgia, and 
various neuropathic pain syndromes, consistently with CCI models 
result [67]. Effectiveness in DNP was once proved – the activity 
was reported at dose range 50-400 mg/day [76], but in other trials 
topiramate failed [77]. Most common observed adverse effects are: 
mild asthenia, dry mouth, irritability, diarrhea, fatigue, sedation, 
nausea, abdominal cramps, and cognitive impairment [67]. 
Biaryl Pyrazoles 
A bis-trifluormethyl derivative (1-[3-[2,5-bis(trifluoromethyl) 
phenyl]phenyl]-5-methyl-pyrazole-3-carboxamide) (Fig. 6) has 
been selected from the group of molecules tested by Merck. The 









Fig. (6). Chemical structure of 1-[3-[2,5-bis(trifluoromethyl)phenyl] 
phenyl]-5-methyl-pyrazole-3-carboxamide. 
In the spinal nerve ligation model in rats (the Chung model) – 
with binding preferences toward calcium and potassium channels, 
as well as sodium channels (IC50 for NaV1.7 of 0.810 M). The 
activity in Chung model was measured 2 h and 4 h after administra-
tion, with 44 and 34% SNL reversal, respectively [79]. The com-
pound is still in preclinical phase. 
Gabapentin 
Gabapentin (1-(aminomethyl)cyclohexaneacetic acid) (Fig. 7) is 
a GABA derivative. Its main mechanism of action, through binding 
to 2 subunit, is inhibition of voltage-gated calcium channels. The 
additional mechanism is related with the above, i.e. inhibition of 
glutamate release, relieving neuronal hyperexcitability [80, 81]. It is 
a well known antiepileptic drug with proved preclinical and clinical 
efficacy in epilepsy and pain. Its MES ED50 is 78.2 mg/kg b.w. 
(mice, i.p.). It is also active in audiogenic seizures with ED50=2.5 
mg/kg b.w. (DBA/2J mice, p.o.) and hippocampal kindling with the 
lowest effective dose 30 mg/kg b.w. (rats, i.p.), as well as clonic 
seizure model with use of metrazole (MET) ED50=47 mg/kg b.w. 
(mice, i.p.) and 52 mg/kg b.w. (mice, p.o.) [82]. Its clinical efficacy 
is proved in adjunctive therapy in partial seizures (by Pfizer) at 
doses 600-1800 mg/day [83, 84], also with paediatric patients [85]. 
The main adverse event observed is transient drowsiness [84]. It is 
inconsistent with preclinical efficacy with MET-evoked seizures 






Fig. (7). Chemical structure of gabapentin. 
Gabapentinhas become a standard medication for neuropathic 
pain. However, its analgesic activity is based on a glutamate- 
dependent mechanism in the brainstem (locus coeruleus) [87]. In 
some reports it is used as a positive control in the SNL model, ad- 
ministered s.c. to rats [25, 88]. It significantly reduces spontaneous 
activity of spinal neurons in the Chung model at doses 10-100 
mg/kg b.w. [25], while ED50 in another research is 32 mg/kg b.w. 
(Table 1) [30]. In most clinical trials gabapentin was used at daily 
doses of 1200 mg or more – the dosage started at 300 mg/day and 
was titrated until reaching 1200, 2400, or 3600 mg/day. Many stud- 
ies for the treatment of neuropathic pain syndromes such as DNP 
and PHN were successful [89-95]. Additionally, the drug is an ef- 
fective treatment for cancer-related neuropathic pain [96, 97]. Re- 
cently, extended release of gabapentin proved effective and well 
tolerated for the treatment of diabetic polyneuropathic pain [98]. 
Retigabine 
Retigabine (D-23129, ethyl N-[2-amino-4-[(4-fluorophenyl) 
methylamino]phenyl]carbamatic acid ethyl ester, ezogabine) (Fig. 
8) has been documented to exert its anticonvulsant action via multi-
ple mechanisms. There is evidence indicating that it increases 
GABAergic transmission in the central nervous system and acti-
vates KV7 potassium channels [81, 99, 100]. Such various mecha-
nisms result in broad protection against seizures in MES, ScMET 
(s.c. metrazol-induced seizures), as well as amygdala kindling 
model considered as a model for epileptogenesis [101]. The MES 
ED50s are 9.3 mg/kg b.w. (mice, i.p.) and 2.9 mg/kg b.w. (rats, i.p.). 
Other ED50s are: 13.5 mg/kg b.w. (ScMET, mice, i.p.), and 18.6 
(ScPic, subcutaneous picrotoxin, mice, i.p.) [102]. It was tested in 
clinics at doses 600 and 900 mg/day as well as 600-1200 mg/day as 
an adjunctive therapy for partial onset seizures and these doses 
proved effectiveness [103, 104]. Most commonly reported adverse 
events were dose-related and included dizziness, somnolence, head-









Fig. (8). Chemical structure of retigabine. 
Retigabine has been proved to reduce nociceptive behaviors in 
rat models of neuropathic pain – chronic constriction injury and 
spared nerve injury. It also exerts analgesic activity in the formalin 
test (Table 1) [105, 106]. The assays confirmed antinociceptive 
activity in models of persistent pain, with concomitant unaffected 
normal nociceptive sensory processing. This AED has not entered 
clinical trials for use in pain. 
Pregabalin 
Pregabalin (CI-1008, (S)-3-aminomethyl-5-methylhexanoic 
acid) (Fig. 9), is a derivative of GABA. One of the newest mecha-
nisms found for pregabalin is binding to the 2 subunit of the cal-
cium channels. Similarly to gabapentin, pregabalin is expected to 
increase GABA concentration in neuronal tissues. It also enhances 
activity of glutamate decarboxylase. It is active in MES at ED50s of 
20 mg/kg b.w. (mice, p.o.) and 1.8 mg/kg b.w. (rats, p.o.). Activity 
in audiogenic seizures (Frings mice) also has been proved at doses 
3 and 10 mg/kg b.w. p.o. (Table 1) [101]. A recent review found 38 
randomized clinical trials related with pregabalin and its use, with 
the most common dose of 330 mg (controlled release) [107]. The 
most typical adverse events included dizziness, vertigo, incoordina-
tion, balance disorder, ataxia, diplopia, blurred vision, and sleep 
disorders [107, 108]. Moreover, pregabalin is contraindicated in 
juvenile myoclonic epilepsy as it can worsen seizures [109]. 
Pregabalin is active in the Chung model for mechanical allo-
dynia at doses 3-30 mg/kg b.w. (rats, p.o.) [110]. Then, numerous 
controlled clinical trials have shown the efficacy and safety of pre-
gabalin in patients with painful DPN or PHN. In the studies the 
Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain Current Medicinal Chemistry,  2011 Vol. 18, No. 28      4349 
patients who received pregabalin at dosages of 300 mg/day [111 - 
113] or 600 mg/day [112-115] experienced significant reductions in 
pain compared with placebo. Recently, flexible-dose pregabalin 
(150-600 mg/day) led to a statistically significant reduction in pain 
scores in patients with neuropathic pain due to DPN, PHN or post-
traumatic nauropathic pain [116, 117]. Pregabalin 150 to 600 
mg/day was also shown to reduce pain in older patients (age  65 






Fig. (9). Chemical structure of pregabalin. 
Pregabalin, as Lyrica™, is marketed for the treatment of pe-
ripheral and central neuropathic pain in adults. The treatment can be 
started at a dose of 150 mg/day for treating neuropathic pain. Based 
on individual patient response and tolerability, the dosage may be 
increased to 300 mg/day after an interval of three to seven days, and 
if needed, to a maximum dose of 600 mg/day after an additional 
seven-day interval [3]. 
2. GABA Modulators 
Influence on GABAergic system can be performed via multiple 
mechanisms: binding to GABA receptors (ionotropic or me-
tabotropic), enhancement of GABA synthesis through GAD (L-
glutamic acid decarboxylase) activation (in case of valproic acid), 
or inhibition of GABA catabolism: 
• inhibition of GABA-T (-aminobutyric acid transaminase) 
shown by valproic acid and vigabatrin,  
• inhibition of SSADH (succinic semialdehyde dehydro-
genase) by valproic acid, or 
• inhibition of GAT-1 (-aminobutyric acid transporter) ex-
hibited by tiagabine [119]. 
As it can be noticed, it usually appears as a mixture of mecha-
nisms. 
Valproic Acid Derivatives 
Valproic acid (2-propylpentanoic acid, VPA) (Fig. 10) acts by a 
combination of mechanisms related with GABAergic system en-
hancement (enhancement of activity of GAD resulting in enhanced 
synthesis of GABA, and inhibiting GABA metabolism – via inhibi-
tion of GABA-T and inhibition of SSADH) as well as reduction of 
NMDA-receptor mediated glutamate excitation, and inhibition of 
serotonergic system [119, 120]. Valproic acid is one of the most 
active anticonvulsants, exhibiting ED50 in MES 485 mg/kg b.w. 
(rats, p.o.), or 6Hz ED50=126 (mice, i.p.) (with protection index 
TD50/ED50 1.6) [121]. At the same time it is one of the most toxic 
AEDs (causing hepatotoxicity, teratogenicity, nausea, dizziness, 
and consequently interactions with other drugs, rash, skin inflam-
mation, etc.). 
The role of this drug in neuropathic pain treatment is still un-
clear. Although Kochar et al., revealed that sodium valproate is 
well-tolerated, and provides significant subjective improvement in 
DNP [122, 123], Otto et al. proved that valproic acid has no effect 
on pain in polyneuropathy [124]. The position of VPA in treatment 
is so strong that many efforts have been put to develop its second 
and third generations, in order to limit the side effects, without loss 
of activity. 
Valpromide (2-propylpentanamide, VPD) (Fig. 10), the amide 
of valproic acid, was synthesized as one of the very first valproic 
acid derivatives due to premises that teratogenic activity was related 
with carboxylic group of the molecule. Indeed, valpromide is not 
teratogenic in VPA-induced teratogenicity model in mice. Valpro-
mide is both active in MES with MES ED50=32 mg/kg b.w. (rats, 
p.o.) and ScMET ED50=59 mg/kg b.w. (rats, p.o.). It exhibits pro-
tection index MES ED50/TD50 =2.7, which shows a more safe, 






Fig. (10). Chemical structures of valproic acid and valpromide. 
Its activity in the SNL model for neuropathic pain is supported 
by ED50=61 mg/kg b.w. (rats, i.p.) [125]. 
The close analogs of valpromide constitute valnoctamide and 
valrocemide (N-valproyl glycinamide, TV 1901) (Fig. 11). An in-
teresting fact can be seen when comparing the anticonvulsant activ-
ity of the racemate (R,S) and 2R,3S and 2S,3S enantiomers of val-
noctamide with their analgesic results (Chung model) (Table 1). 
Racemate seems the optimal configuration for the anticonvulsant 
activity (MES ED50 29 mg/kg b.w. rats, i.p.), when 2S,3S enanti-
omer is the most active compound in the Chung model, exhibiting 
ED50 39 mg/kg b.w. (rats, i.p.) [88]. 
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Fig. (11). Chemical structures of valnoctamide and valrocemide. 
Valrocemide is a drug candidate in preclinical trials, active in 
MES with ED50 of 151 mg/kg b.w. (mice, i.p.), exhibits protection 
index PI (TD50/ED50) of 2.2. It is also active in ScMet test (mice, 
i.p.) with ED50 of 132 mg/kg.b.w. The ED50 in rats, p.o. is 73.1 
mg/kg b.w. in MES (PI>13.7) [126]. 
Some very interesting discussion can arise from the results of 
Bialer et al. on stereochemical aspects of structure-activity relation-
ship (Fig. 12). The obtained R,S-, R-(-), and S-(+)-propylisopropyl-
acetamide (PID) reveal various activities in MES (i.e. 122, 110, and 
145 mg/kg b.w., respectively) in mice, i.p., and 31, 16, and 25 
mg/kg b.w., respectively in rats, p.o.[127]. These results show that 
the most potent enantiomer is the R one. However, from the thera-
peutic point of view and taking under consideration extrapolation of 
results into humans, the differences do not necessarily have to be 











Fig. (12). Chemical structures of racemic PID and its enantiomers (R,S, R, 
and S, respectively). 
Since valrocemide, other valproic acid derivatives have been 
developed [25], revealing significant activity in neuropathic pain, 
with primary anticonvulsant mechanism of action. The design of 
molecules predicted avoiding teratogenicity and hepatotoxicity – 
the two major disadvantages of the parent compound. The study 
concerned the following derivatives (Figs. 13 and 14): 
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• TMCA (2,2,3,3-tetramethylcyclopropanecarboxylic acid),  
• TMCD (2,2,3,3-tetramethylcyclopropanecarboxamide),  
• MTMCD (N-methyl-2,2,3,3-tetramethylcyclopropane car-
boxamide),  















Fig. (14). Chemical structures of MTMCD and TMCU. 
They were reported as new valproic acid derivatives. Among 
them, TMCA showed only weak anticonvulsant activity in rats 
while others were found to posses broad-spectrum anticonvulsant 
properties. At the same time all new derivatives: TMCA, TMCD, 
MTMCD and TMCU showed dose-related antiallodynic activity in 
SNL model at doses that did not cause motor impairment in the 
rotarod test [25].  
Diisopropylacetamide (DID) (Fig. 15) is another amide deriva-
tive of valproic acid that showed antiallodynic activity in the SNL 
model. The lowest dose of the compound needed to significantly 





Fig. (15). Chemical structure of DID. 
Kaufmann et al. reported in 2009 about a wide series of novel 
amide, N-methyl amide and urea derivatives of valproic acid ana-
logues which consists of 17 compounds [129]. All compounds were 
tested in MES and ScMet in mice after i.p. administration as well as 
in SNL model in rats after i.p. administration. Some of them were 
also evaluated in pilocarpine induced status epilepticus (rats p.o.). 
The neurotoxicity was evaluated as motor impairment or sedation. 
Compounds possessed five to nine carbon atoms and some of them 
additionally carried N-methyl moiety. In this group, compounds 
which had 8 carbon atoms showed best activity in both antiallo-
dynic as well as in anticonvulsant tests. At the same time com-
pounds with 9 carbon atoms showed narrower safety margin be-
tween antiallodynic activity and motor impairment and sedation 
although they were more potent antiallodynic agents than 8-carbon 
atoms derivatives. Compounds with fewer than 8 carbon atoms 
showed the least anticonvulsant and antiallodynic activity. In the 
presented group the most promising compounds were 3-methyl-2-
propyl-pentanamide and N-carbamoyl-2-ethyl-3-methyl-pentana-
mide exerting good anticonvulsant properties with ED50 values in 
pilocarpine test of status epilepticus of 84 mg/kg (rats, p.o., 0.5 h) 
and 23 mg/kg, respectively (rats, p.o., 0.0 h). Moreover, 2-
isopropyl-3-methyl-pentanamide ED50 50 mg/kg. In a test for neu-




piperidinecarboxylic acid) (Fig. 16) is a derivative of nipecotic acid, 
used as a hydrochloride, with mechanism of action based on GABA 
re-uptake inhibition, causing increase of extracellular concentration 
of GABA. It is more active in ScMET test than in MES, with ED50s 
1 mg/kg b.w. (ScMET, mice, i.p.), 11.5 mg/kg b.w. (ScMET, rats, 
i.p.) and 4 mg/kg b.w. (ScMET, rats, p.o.), compared to 40 mg/kg 
b.w. (MES, rats, p.o.) (Table 1). Activity in prevention audiogenic 
seizures is documented by ED50 0.4 mg/kg b.w. (Frings mice, i.p.) 
[130]. It is indicated for use in adjunctive therapy for partial sei-
zures [10]. 
In a clinical trial for efficacy of TGB as add-on therapy in pa-
tients with drug resistant focal epilepsy, tiagabine was administered 
at dose 30-50 mg/kg as an adjuvant drug to valproic acid or carba-
mazepine. Beneficial effect of TGB on seizure reduction was seen 
especially with VA. The most common adverse effects were dizzi-
ness and somnolence [131]. Another clinical trial was conducted in 
patients with refractory epilepsy of whom the mean number of 
AEDs taken prior to tiagabine was 5. TGB tested at starting dose of 
5 or 10 mg/day which was increased another 5 or 10 mg/day every 
week to achieve the level of 20-40 mg/day. 35% of patients bene-
fited from the drug, mostly with higher doses. The most common 






Fig. (16). Chemical structure of tiagabine.  
Tiagabine was tested for potential anti-allodynic effects in the 
nerve ligation (Chung) model of neuropathic pain. The compound 
showed dose-dependent anti-allodynic and antinociceptive activity 
in rats, i.p., with significant increases in response threshold to tac-
tile stimulation. In a test for analgesic activity – the formalin test 
(mice, i.p.) – it was active in both acute and inflammatory phase. 
Nevertheless, it had no effects on carrageenan-induced edema in the 
same research [133]. Tiagabine has not been tested in clinical trials 
for use in neuropathic pain. 
Vigabatrin 
Vigabatrin (4-aminohex-5-enoic acid, VGB) (Fig. 17) exerts 
anticonvulsant mechanism of action based on irreversible inhibition 
of GABA aminotransferase, resulting in increased amount of 
GABA in the synapse. Vigabatrin is ineffective in the MES and 
ScMET tests, but it protects against sound-induced seizures and 
amygdala kindling in mice. It is also active in seizures induced by 
kainic acid. Further in clinical trials vigabatrin exhibited some ac-
tivity in drug resistant complex partial seizures, and in the West 
syndrome. Therefore, VGB is registered for the therapy of partial 
(focal, local) epilepsy as well as infantile spasms. Still, the side 
effects represented by this drug are related with increased concen-
tration of extracellular GABA, including peripheral visual field 





Fig. (17). Chemical structure of vigabatrin.  
In order to verify activity of viagabatrin in the Bennett model, a 
modified procedure of sciatic nerve ligation has been performed 
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and the activity was observed at the least 10 mg/kg b.w. (rats, p.o.). 
The drug reversed allodynia and hyperalgesia similarly to carba-
mazepine and valproic acid [135]. The results proved that GABAer-
gic transmission plays role in the mechanism involved in 
neuropathic pain. More recently, antinociceptive activity of VGB 
was reported in one of the acute pain models– hot plate test in mice, 
i.p.[136]. However, no clinical trials considering its activity in pa-
tients with neuropathic pain have been reported yet and its potential 
effectiveness needs to be proved in more advanced studies. 
3. Synaptic Vesicle 2A Binding Drugs 
Levetiracetam 
Levetiracetam, (UCBLO59, (S)--ethyl-2-oxo-1-pyrolidine 
acetamide) (Fig. 18) is the S enantiomer of etiracetam, a pyrrolidine 
derivative with antiepileptic properties. Although the precise 
mechanism of action of levetiracetam is not fully understood, the 
drug appears to bind specifically to synaptic vesicle protein 2A 
(SV2A) in both brain and spinal cord [137, 138]. 2A protein 
inhibits calcium release from intraneuronal stores, opposing the 
activity of negative modulators of GABA- and glycin-gated cur-
rents and inhibiting excessive activity between neurons. 
Anticonvulsant properties of levetiracetam are untypical – it is 
inactive in MES, but active in audiogenic seizures in Frings mice 
and in 6 Hz test in mice. In electroshock kindling (mice, i.p.) 
ED50=7 mg/kg b.w., and in MET kindling – 36 mg/kg b.w. (mice, 







Fig. (18). Chemical structure of levetiracetam.  
This AED has been shown to be active in animal models of 
neuropathic pain. In the chronic constriction injury (Bennett) model 
the antihyperalgesic effect observed with the compound appeared 
from a dose of 540 mg/kg whereas in the diabetic rat model at a 
dose of 17 mg/kg (Table 1) [140]. 
Few clinical trials have been conducted to evaluate effective-
ness of levetiracetam in the treatment of neuropathic pain and most 
of those that have been carried out do not show any benefit in com-
parison to the use of placebo. Levetiracetam failed to relieve pe-
ripheral neuropathic pain in postmastectomy pain syndrome 
(PMPS) at 3000 mg/day [141], the drug was also ineffective in 
painful polyneuropathy at the same dose [142] and in patients with 
spinal cord injury (SCI) at 2000 mg/day [143]. This may result 
from no evidence that SV2A protein would play a role in neuro-
pathic pain etiopathogenesis. 
Brivaracetam 
Brivaracetam (UCB34714, (2S)-2-[(4R)-2-oxo-4-propylpyr-
rolidin-1-yl]butanamide) (Fig. 19) is a propyl homolog of 
levetiracetam. Introduction of the propyl moiety changed the ring 
carbon in position 3 into a chiral one. Brivaracetam, besides bind-
ing to synaptic vesicle protein 2A (SV2A) which is its main mecha-
nism [144] also inhibits sodium channels. Just like levetiracetam, 
this compound is not active in the MES and ScMET tests. Its anti-
convulsant activity is supported with ED50 in corneal kindling test 
1.2 mg/kg b.w. (mice, i.p.), in audiogenic seizures 2.4 mg/kg b.w. 
(Frings mice, i.p.), and 6 Hz seizures 4.4 mg/kg b.w., as well as 
amygdala kindled mice 68.3 mg/kg b.w. and corneal kindling at 1.2 
mg/kg b.w. (mice, i.p.). In amygdala kindled rats it was effective at 
ED50 44 mg/kg b.w. (i.p.) and 45 mg/kg b.w. (p.o.) [81]. 
This drug is being developed by UCB Pharma, after Phase IIb 
in which it was well tolerated at doses 50-150 mg/day. It was also 
effective in the treatment of focal epilepsy at 100 mg/day in Phase 
III trial [81]. However, Phase III clinical trial for monotherapy at 
doses 50 and 100 mg/day was terminated. An interim analysis re-
vealed that the study was unlikely to attain a positive outcome for 
the efficacy analysis. No safety concerns were detected [145]. Most 
common adverse events were: aggression, anxiety, irritability, in-









Fig. (19). Chemical structure of brivaracetam.  
This AED is also active in CCI models of pain [81] as well asin 
clinical trials for activity in PHN at 200 mg/day and the study com-
pleted in 2010. Unfortunately, no results in humans have been 
reported until July 2011 [146].  
4. Glutamate Receptor Modulators 
Both NMDA and AMPA receptors have been considered as in-
teresting targets for potential analgesics active in neuropathic pain. 
Protection against kainic acid – induced currents suggests neuropro-
tection. On the other hand, activity on NMDA receptor turns the 
molecule more towards pain indication [147, 148]. 
CNS-5161 – NMDA Antagonist 
CNS-5161 (N'-(N-(2-chloro-5-(methylmercapto)phenyl)-N-(3-
(methylmercapto)phenyl)-N-methylguanidine hydrochloride) (Fig. 
20) is a novel and selective noncompetitive antagonist of the 
NMDA subset of glutamate receptors in the mammalian brain [149, 
150]. Preclinical studies have demonstrated compound’s anticon-









Fig. (20). Chemical structure of CNS-5161. 
Consistently with the mechanism of action, the main potential 
clinical applications of CNS-5161 are analgesia and neuroprotec-
tion [151, 152]. In the safety study it was well tolerated up to the 
dose 0.5 mg and the most common adverse events were hyperten-
sion, headache, and mild visual disorders [151]. The study was not 
sufficiently powered to study analgesic efficacy, although the activ-
ity was observed. The compound is being developed by CeNeS 
(Paion, formerly Cambridge NeuroScience) for the potential treat-
ment of neuropathic pain. 
NS-1209 – AMPA Antagonist 
NS-1209 (NS-479; SPD-502, [8-methyl-5-(4-(N,N-dimethylsul-
famoyl)phenyl)-6,7,8,9-tetrahydro-1H-pyrrolo[3,2-h]-iso-quinoline 
2,3-dione-3-O-(4-hydroxybutyric acid-2-yl)oxime] (Fig. 21) is a 
water-soluble competitive and potent AMPA/ GluR5 (glutamate 
receptor subtype 5) selective antagonist [153]. NS-1209 has been 
found to provide strong protection against status epilepticus in-
duced by electrical stimulation of the amygdala or subcutaneous 
administration of kainic acid in rats, with bolus injection of 50 
mg/kg b.w. followed by infusion of 5mg/kg*h (intravenous, i.v.). It 
is interesting, that so far status epilepticus had been associated with 
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mechanisms of action like GABAA antagonism, NaV channels inhi-
bition, NMDA receptor inhibition, or modulation of calcium influx 
[154]. At infusions dosing 5mg/kg*h no mortality of animals was 
observed. Additionally, NS-1209 reveals some neuroprotective 
activity against status-induced hippocampal neurodegeneration, 












Fig. (21). Chemical structure of NS-1209. 
In the chronic constriction injury rat model of neuropathic pain, 
NS-1209 (3 and 6 mg/kg b.w., i.p.) exerts reduction of mechanical 
allodynia and hyperalgesia responses to von Frey hair and pin prick 
stimulation of the injured hind paw (Table 1). The compound was 
administered to rats 2–7 weeks after sciatic nerve injury. Addition-
ally, injection of NS-1209 produced attenuation of the cold score 
response after application of ethyl chloride to the injured hind paw 
[155]. NS-1209’s effect on mechanical allodynia is in accordance 
with the long-lasting in vivo effects observed in electrophysiologi-
cal experiments as described previously [153].  
In clinical trials, NS-1209 has been shown to possess a long du-
ration of action and is well tolerated by humans at plasma levels 
two to four times greater than preclinical levels responsible for 
neuroprotection in rats. Thus, some of the opportunities for the use 
of NS-1209 may include an adjunct therapy for the prevention of 
post-operative pain [155]. One clinical study has been completed 
for use of NS-1209 and lidocaine for patients with peripheral neu-
ropathic pain – the patients were administered 322 mg of NS-1209 
and 5 mg of lidocaine. As a result, both drugs were significantly 
better than placebo in alleviating brush-evoked mechanical allo-
dynia and they both significantly reduced cold allodynia, but in 
both allodynias NS-1209 did not differ from lidocaine [156].  
Indantadol (CHF3381) – NMDA antagonist 
CHF3381 (2-(2,3-dihydro-1H-inden-2-ylamino)acetamide hy-
drochloride, V3381) (Fig. 22) is a low-affinity, noncompetitive 
NMDA receptor antagonist and reversible MAO-A (monoami-
nooxydase) inhibitor. Its MES ED50 in rats, p.o. is 21 mg/kg b.w. It 
displayed neuroprotective effects after kainate-induced seizures in 
preclinical studies, and exhibited anticonvulsant and antihyperalge-






Fig. (22). Chemical structure of indantadol. 
The compound was under development by Vernalis plc, under 
license from Chiesi Farmaceutici SpA, for the treatment of neuro-
pathic pain. It produced a significant suppression of nociceptive 
behavior and completely blocked mechanical allodynia and hyper-
algesia in the capsaicin pain model at 100 and 200 mg/kg b.w. in 
rats, p.o. [158]. Indantadol was shown to be active in a variety of 
rodent models of acute, inflammatory, and neuropathic pain. In rats 
with a sciatic nerve injury (CCI), indantadol relieved both cold and 
mechanical allodynia (ED50 100 mg/kg, rats, p.o.) [159]. Its me-
tabolites are CHF3567 and 2-aminoindane. Its anticonvulsant activ-
ity seems stronger than analgesic properties. Still, the analgesic 
activity in all animal models remains close to the upper limit in the 
protection gap between ED50 in MES and TD50 in rotorod=113 
mg/kg b.w. (Table 1) [160]. 
One clinical trial has been noticed in a Phase II study on safety, 
tolerability and efficacy of indantadol in DNP at dose 400 mg, but 
the status of the study has not been updated since 2008 [161]. 
Tezampanel and NGX-426 – AMPA/Kainate Receptor Antago-
nists 
NGX-426 is the oral ester prodrug of tezampanel (NGX-424, 
LY293558, (3S,4aR,6R,8aR)-6-[2-(1H-tetrazol-5-yl)ethyl]decahy-
droisoquinoline-3-carboxylic acid) (Fig. 23), although the structure 
has not been published.  Tezampanel and NGX-426 are ionotropic 
glutamate receptor antagonists that target the AMPA and kainate 
subtype receptors.Tezampanel is an anticonvulsant and exhibits 
neuroprotective activity, which is not surprising, taking into ac-
count that AMPA receptors are involved in kindling of the 
amygdala in mice [162]. 
Tezampanel was tested in rats for activity after plantar incision 
at dose 34mol/kg (parenteral). It is interesting that tezampanel 
failed in a clinical trial for analgesic activity, however, it reduced 
capsaicin-evoked hyperalgesia in humans. Adverse events observed 
were hazy vision and sedation [163]. 
NGX-426 is developed for its analgesic activity only. The com-
pound is under development by Raptor Pharmaceutical (previously 
Torrey Pines Therapeutics) for the potential treatment of neuro-










Fig. (23). Chemical structure of tezampanel. 
III. CONCLUSIONS 
This review shows again that if a drug is active in an animal 
model, the results cannot be extrapolated to humans directly, and 
that the risk of failure in clinical trials is significant. Lacosamide 
can serve as an example, since one clinical trial on DNP failed even 
though the drug was active in the streptozocin model. This phe-
nomenon is not typical for neuropathic pain, as gabapentin active in 
MET-evoked seizures in rodents did not show efficacy in absence 
epilepsy in children. 
Considering strategies for drug development, it is already a 
phenomenon that companies or even researchers turn their drug 
discovery projects toward a larger market which is pain, due to 
possible efficacy.These decisions can be seen for e.g. CNS-5161 or 
NGX-426. One reason stated in the introduction is that hyperexcit-
ability of neurons is both a hallmark for epilepsy and neuropathic 
pain. The reason coming up from the search of the literature is that 
efficacy, though not always based on the very same mechanism of 
action in epilepsy and pain, can be expected. Among older drugs, 
the data show that ED50s of drugs presented in the review usually 
stay in the same range in anticonvulsant and analgesic tests. The 
newest analgesic drugs, however, have been designed in a way that 
favors specific analgesic and not antiepileptic profile, probably 
leading to forthcoming separation of the therapeutic groups. 
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Table 1. Anticonvulsant and Analgesic Properties of Selected Anticonvulsants 
 
Figure Drug Name 
Anticonvulsant properties 
Test ED50 (species, route of administration) 
Analgesic properties 
Test ED50 (species, route of administration) 
1 Carbamazepine 
MES 7.81 (mice, i.p.) 
MES 17 (mice, p.o.) 
MES 3.4 (rats, i.p.) 
MES 8.1 (rats, p.o.) 
[10, 27, 34] 
SNL 0.5 (rats, s.c.)* 
[30] 
1 Oxcarbazepine 
MES 14.12 (mice, i.p.) 
MES 6.1 (rats, i.p.) 
MES 10.0 (rats, p.o.) 
[27, 34] 
SNL 10 (rats, i.p.)* 
[35] 
2 Lamotrigine 
MES 7.47 (mice, i.p.) 
MES 3.7 (mice, p.o.) 
MES 1.26 (rats, p.o.) 
AGS 2.39 mice, i.p.) 
hippocampal kindling 61.3 (rats, i.p.)** 
[42, 43] 
SNL 12 (rats, p.o.) 
[46] 
3 Lacosamide 
MES 4.5 (mice, i.p.) 
MES 3.9 (rats, i.p.) 
AGS 0.63 (mice, i.p.) 
[53, 81] 
 
Formalin 32 (mice, i.p.) 
[61] 
4 Zonisamide 
19.6 mg/kg b.w. (mice, p.o.) 
7.9 mg/kg b.w. (rats, p.o.) 
[68] 
Formalin 3-10 (mice, s.c.)* 
[20] 
5 Topiramate 
MES 33 (mice, i.p.) 
MES 47.6 (mice, p.o.) 
MES 15.8 (rats, p.o.) 
[71, 164] 
CCI 20 (rats, i.p.) 
[75] 
7 Gabapentin 
MES 78.2 (mice, i.p.) 
MES 14.8 (rats, p.o.) 
[88] 
SNL 32 (rats, i.p.) 
[88] 
8 Retigabine 
MES 9.3 (mice, i.p.) 
MES 2.9 (rats, i.p) 
[81] 
SNL >20 (rats, p.o.) 
Formalin 20 (rats, p.o.)* 
[106] 
9 Pregabalin 
MES 20 (mice, p.o.) 
MES 1.8 (rats, p.o.) 
AGS 3 (mice, p.o.)* 
[81] 
SNL 15.9 (rats, p.o.) 
Formalin 4.8 (rats, p.o.)* 
[165] 
10 Valproic acid 
MES 263 (mice, i.p.) 
MES 829 (mice, p.o.) 
MES 212 (rats, i.p.) 
MES 485 (rats, p.o.) 
6Hz 126 (mice, i.p.) 
[81, 121, 127] 
SNL 269 (rats, i.p.)  
[127] 
11 Valrocemide 
MES 151 (mice, i.p.) 
MES 73.1 (rats, p.o.) 
[88] 
SNL 52 (rats, i.p.) 
[129] 
11 R,S-Valnoctamide 
MES 29 (rats, i.p.) 
[88] 
SNL 52 (rats, i.p.) 
[88] 
11 2R,3S-Valnoctamide 
MES 34 (rats, i.p.) 
[88] 
SNL 61 (rats, i.p.) 
[88] 
11 2S,3S-Valnoctamide 
MES 64 (rats, i.p.) 
[88] 
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(Table 1). Contd….. 
Figure Drug Name 
Anticonvulsant properties 
Test ED50 (species, route of administration) 
Analgesic properties 
Test ED50 (species, route of administration) 
12 R,S-PID 
MES 122 (mice, i.p) 
MES 31 (rats, p.o.) 
MES 22 (rats, i.p.) 
[127] 
SNL 42 (rats, i.p.) 
[127] 
12 R-PID 
MES 110 (mice, i.p.) 
MES 16 (rats, p.o.) 
MES 54 (rats, i.p.) 
[127] 
SNL 48 (rats, i.p.) 
[127] 
12 S-PID 
MES 145 (mice, i.p.) 
MES 25 (rats, p.o.) 
MES 49 (rats, i.p.) 
[127] 
SNL 46 (rats, i.p.) 
[127] 
13 TMCD 
MES >250 (rats, i.p.) 
[25] 
SNL 85 (rats, i.p.) 
[25] 
13 TMCA 
MES>150 (rats, i.p.) 
[25] 
SNL 181 (rats, i.p.) 
[25] 
14 MTMCD 
MES 82 (rats, i.p.) 
[25] 
SNL 41 (rats, i.p.) 
[25] 
14 TMCU 
MES 29 (rats, i.p.) 
[25] 
SNL 171 (rats, i.p.) 
[25] 
15 DID 
MES 51 (rats, i.p.) 
[125] 
SNL 58 (rats, i.p.) 
[125] 
16 Tiagabine 
MES 40 (rats, p.o.) 
ScMET 4 (rats, p.o.) 
ScMET 1 (mice, i.p.) 
AGS 0.4 (mice, i.p.) 
[10] 
SNL 72.8 (rats, i.p.)** 
Formalin 10 (mice, i.p.)* 
[133] 
18 Levetiracetam 
electrical kindling 7 (mice, i.p.) 
MET kindling 36 (mice, i.p.) 
[139] 
CCI 540 (rats,i.p.) 
Streptozocin 17 (rats, i.p.) 
[140] 
19 Brivaracetam 
corneal kindling 1.2 (mice, i.p.) 
AGS 2.4 (mice, i.p.) 




Electroshock seizure threshold increase 50 (mice, i.v.) 
[153] 
CCI 3 (rats, i.p.) 
[155] 
22 Indantadol 
MES 24 (mice, i.p.) 
MES 21 (mice, p.o.) 
MES 7.5 (rats, i.p.) 
MES 21 (rats, p.o.) 
[160] 
SNL 100 (rats, p.o.)* 
[160] 
*the result is shown as the minimal effective dose MED as the ED50 was not determined; ** Mol/kg. 
MES – maximum electroshock seizures; AGS – audiogenic seizures; SNL – spinal nerve ligation; CCI – chronic constriction injury; ND – not determined; MET – metrazol, pentyle-
netetrazol. 
The probable reason for the above mentioned fact is a signifi-
cant difference in strategiesfor drug discovery in both indications. 
Since epileptogenesis is a complex process with various causes and 
epilepsy has multiple symptoms, discovery of anticonvulsants is 
still performed by screening in vivo [10]. As a result, the drugs 
registered on the market exert multiple mechanisms of action and 
no specificity towards any ion channel/receptor subtype. Even 
modern AEDs, such as retigabine, though binds to KV7 channel, 
also influences GABA system. On the contrary, analgesics are 
screened in vitro, for specific targets such as ion channels, i.e. 
NaV1.3, NaV1.7 and NaV1.8, or ionotropic glutamate receptors such 
as NMDA, AMPA, or kainic acid, since the mechanisms of neural 
damage and induction of neuralgiaare becoming better understood. 
In such cases there are premises to receive analgesics without anti-
convulsant properties, as in the case of e.g.NGX-426. It is also a 
premise to receive better tolerated drugs, exhibiting fewer side ef-
fects. In the end, they are hoped to prove effectiveness in the clini-
cal trials and serve as therapy afterwards. 
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